CEL-SCI Corporation (“CEL-SCI” or the “Company”) (NYSE:CVM), a Phase 3 cancer immunotherapy company,today announced that it intends to offer to sell shares of its common stock in an underwritten public offering. The Company expects to grant the underwriter a 45-day option to purchase up to an additional 15% of the number of shares of common stock sold in this offering to cover over-allotments, if any. All of the shares of common stock are being offered by the Company. The offering is subject to market conditions and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
The Company intends to use the net proceeds from this offering to fund the continued development of Multikine* and for general corporate purposes.
ThinkEquity is acting as sole book-running manager for the offering.
